Anti-Inflammatory Drug Discovery

Author:   Jeremy Levin ,  Stefan Laufer ,  David E. Thurston ,  David Fox
Publisher:   Royal Society of Chemistry
Volume:   26
ISBN:  

9781849735346


Pages:   432
Publication Date:   18 July 2012
Format:   Electronic book text
Availability:   Temporarily unavailable   Availability explained
The supplier advises that this item is temporarily unavailable. It will be ordered for you and placed on backorder. Once it does come back in stock, we will ship it out to you.

Our Price $686.40 Quantity:  
Add to Cart

Share |

Anti-Inflammatory Drug Discovery


Overview

Full Product Details

Author:   Jeremy Levin ,  Stefan Laufer ,  David E. Thurston ,  David Fox
Publisher:   Royal Society of Chemistry
Imprint:   Royal Society of Chemistry
Volume:   26
ISBN:  

9781849735346


ISBN 10:   1849735344
Pages:   432
Publication Date:   18 July 2012
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Electronic book text
Publisher's Status:   Active
Availability:   Temporarily unavailable   Availability explained
The supplier advises that this item is temporarily unavailable. It will be ordered for you and placed on backorder. Once it does come back in stock, we will ship it out to you.

Table of Contents

Reviews

Author Information

Professor Laufer has held the chair for Pharmaceutical/Medicinal Chemistry at the University of Tubingen since 1999. He received his Ph.D. from the University of Regensburg (1989) and obtained his Venia Legendi (habilitation) in Pharmaceutical Chemistry from the University of Mainz (1997). From 1990-99 he held senior research and executive positions in pharmaceutical industry. His research interests cover major aspects of anti-inflammatory drug discovery and development, including design, synthesis, biological screening, metabolism, and bioanalytics. The molecular targets that have been the focus of research in his laboratory are the key enzymes of the arachidonate cascade and protein kinases. Two drug candidates from his lab have reached clinical development stages (ML3000-Licofelone, a COX/LOX Inhibitor and CSB3595, a p38 MAPK/PDE4 inhibitor). Professor Laufer has authored 230 publications and is the inventor of 36 patent families. Jeremy I. Levin has been a Director of Medicinal Chemistry for Boehringer-Ingelheim in Ridgefield, Connecticut, since 2010. He received his B.A. from Johns Hopkins University in 1978 and a Ph.D. in organic chemistry with Professor Steven Weinreb at the Pennsylvania State University in 1983. Following a post-doctoral fellowship at the University of California at Irvine with Professor Larry Overman, he spent 25 years in the pharmaceutical industry at American Cyanamid (Lederle laboratories) and Wyeth Research. Dr. Levin has worked in a variety of therapeutic areas including CNS, inflammation and immunology, and oncology. He is the author/co-author of more than 75 papers and an inventor on more than 60 U. S. Patents.

Tab Content 6

Author Website:  

Countries Available

All regions
Latest Reading Guide

NOV RG 20252

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List